AI and The Future of Seed Development: A Genome Editor’s Perspective

Chrysalis is hosting an open house at its Raleigh facility. This is an opportunity to tour cleanrooms and chat with the Chrysalis team. Bring your questions, your colleagues, and your curiosity. 

Durham-based SelSym Biotech, a biomedical company with roots at North Carolina State University, has secured an equity investor and partner to help it develop a novel therapy to control emergency bleeding.

Durham-based Humacyte, a regenerative medicine company, will soon begin a first-in-human clinical study of its bioengineered blood vessel in patients undergoing coronary artery bypass grafting (CABG).

The U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase 2a study.